Molecular Partners (NASDAQ:MOLN) Trading Down 1.5% – Should You Sell?

Shares of Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) fell 1.5% during trading on Monday . The company traded as low as $4.90 and last traded at $4.9240. 137 shares traded hands during mid-day trading, a decline of 97% from the average session volume of 4,685 shares. The stock had previously closed at $5.00.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Molecular Partners in a research report on Monday, December 22nd. JPMorgan Chase & Co. reduced their price objective on Molecular Partners from $4.00 to $3.75 and set a “neutral” rating on the stock in a research note on Monday, December 8th. Finally, HC Wainwright assumed coverage on Molecular Partners in a research note on Tuesday, January 27th. They issued a “buy” rating and a $13.00 target price for the company. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $9.58.

Molecular Partners Stock Performance

The firm has a market capitalization of $198.83 million, a price-to-earnings ratio of -2.56 and a beta of 1.07. The stock’s fifty day moving average is $4.38 and its two-hundred day moving average is $4.06.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Molecular Partners stock. SmartHarvest Portfolios LLC purchased a new stake in Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 12,311 shares of the company’s stock, valued at approximately $54,000. Institutional investors own 26.55% of the company’s stock.

Molecular Partners Company Profile

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company’s development pipeline spans infectious diseases, ophthalmology and oncology.